A Randomized, Placebo-controlled, Double-blind, Multi-center, Phase III Trial to Assess the Efficacy and Safety of Trimodulin (BT588) in Adult Hospitalized Subjects With Severe Community-acquired Pneumonia (sCAP)

996

The main objective of the trial is to assess the efficacy and safety of trimodulin as adjunctive treatment to standard of care (SoC) compared to placebo plus SoC in adult hospitalized subjects with sCAP on invasive mechanical ventilation (IMV). Other objectives are to determine detailed pharmacokinetic (PK) properties of trimodulin in a PK substudy and to determine its pharmacodynamic (PD) properties.

2023-09-09

2025-02-28

2025-04-30

Recruiting

Early phase I

590

Main Inclusion Criteria: 1. Written informed consent. 2. Hospitalized, adult (≥ 18 years of age) subject. 3. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) negative status. 4. Signs of inflammation based on C-reactive protein threshold level. 5. Diagnosis of active pneumonia. 6. Radiological (or other imaging technology) evidence consistent with active pneumonia. 7. Acute respiratory failure requiring IMV. Main Exclusion Criteria: 1. For an incapacitated subject: any indication that the subject's presumed will would be against inclusion in the trial. 2. Pregnant or lactating women. 3. Subjects not willing to use reliable contraceptive measures during the trial and for 15 weeks after the last IMP treatment. 4. Suspected hospital-acquired pneumonia (HAP) including ventilator-associated pneumonia (VAP). 5. Diagnosis of COVID-19 during the last 4 weeks. 6. Subjects that required oxygen therapy due to COVID-19 in the last 6 months. 7. Defined neutrophil counts within 24 hours prior to start of IMP treatment. 8. Defined platelet counts within 24 hours prior to start of IMP treatment. 9. Defined hemoglobin within 24 hours prior to start of IMP treatment. 10. Known hemolytic disease. 11. Known thrombosis or thromboembolic events (TEEs) or known medical history of TEEs or subjects particularly at risk for TEEs. 12. Subject on dialysis or with severe renal impairment within 24 hours prior to start of IMP treatment. 13. Subject with end-stage renal disease (ESRD) or known primary focal segmental glomerulosclerosis (FSGS). 14. Known severe lung diseases interfering with sCAP therapy (e.g., subjects with chronic obstructive pulmonary disease \[COPD\], severe interstitial lung disease \[incl. idiopathic pulmonary fibrosis\], cystic fibrosis, active tuberculosis, chronically infected bronchiectasis, or active lung cancer). 15. Known decompensated heart failure. 16. Known pre-existing hepatic cirrhosis, severe hepatic impairment (Child Pugh score ≥ 9 points), or hepatocellular carcinoma. 17. Known intolerance to proteins of human origin or known allergic reactions to components of trimodulin / placebo. 18. Selective immunoglobulin A (IgA) deficiency with known antibodies to IgA. 19. Known treatment for thorax/head/neck/hematologic malignancies in the last 12 months before screening. 20. Life expectancy of less than 90 days, according to the investigator's clinical judgment, because of medical conditions related neither to sCAP nor to sCAP-associated septic conditions. 21. Morbid obesity with high body mass index (BMI) ≥ 40 kg/m2, or malnutrition with low BMI \< 16 kg/m2. 22. Known treatment with polyvalent immunoglobulin preparations, plasma, or albumin preparations during the last 21 days before screening. 23. Known treatment with predefined medications, during the last 5 days before screening. 24. Any type of interferon during the last 21 days before screening. 25. Ongoing treatment with immunosuppressants other than guideline recommended immunosuppressants for treatment of active pneumonia. 26. Participation in another interventional clinical trial within 30 days before screening or previous participation in this clinical trial.

{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE3'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'interventionModelDescription': 'Subjects will be randomized on a 1:1 basis to receive trimodulin or placebo, stratified by center', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'QUADRUPLE', 'maskingDescription': 'All bottles will be indistinguishable.', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR', 'OUTCOMES_ASSESSOR']}}, 'enrollmentInfo': {'count': 590, 'type': 'ESTIMATED'}}

2024-04-26